Skip to main content
. Author manuscript; available in PMC: 2015 Apr 3.
Published in final edited form as: Cancer Res. 2014 Dec 10;75(3):584–593. doi: 10.1158/0008-5472.CAN-13-3029

Figure 7.

Figure 7

Targeting PDGFRs sensitizes breast cancer cells with Foxq1 overexpression to chemotherapeutic agents. A and B, the effect of imatinib on HMLER/Foxq1 (A) or 4T1 (B) cells with treatment of various doses of doxorubicin (left) and paclitaxel (right; ***, P < 0.001). C and D, synergistic inhibitory effects of imatinib with doxorubicin (C) or with paclitaxel (D) on HMLER/Foxq1 cells (C) or 4T1 cells (D) induced tumor growth (left) and tumor weight (right) were shown (***, P < 0.001).